- Previous Close
3,005.00 - Open
3,005.00 - Bid 2,985.00 x --
- Ask 2,990.00 x --
- Day's Range
2,970.00 - 3,010.00 - 52 Week Range
2,650.00 - 3,905.00 - Volume
30,893 - Avg. Volume
53,022 - Market Cap (intraday)
208.807B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield 115.00 (3.83%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair care, beauty care, and other cosmetics products; infant care system, gynecological examining table, sterilizer equipment, diagnostic imaging equipment, operating room equipment, non-PVC film, tube, and empty bag, and health supplements. In addition, the company provides integrated services for IV solution. JW Holdings Corporation was founded in 1945 and is based in Gwacheon-si, South Korea.
www.jw-holdings.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 096760.KS
View MorePerformance Overview: 096760.KS
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 096760.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 096760.KS
View MoreValuation Measures
Market Cap
210.07B
Enterprise Value
571.76B
Trailing P/E
3.44
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.24
Price/Book (mrq)
0.92
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
2.47
Financial Highlights
Profitability and Income Statement
Profit Margin
7.05%
Return on Assets (ttm)
7.56%
Return on Equity (ttm)
28.22%
Revenue (ttm)
887.71B
Net Income Avi to Common (ttm)
62.62B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
74.18B
Total Debt/Equity (mrq)
83.60%
Levered Free Cash Flow (ttm)
55.55B